ES2909998T3 - Método para establecer, restablecer y preservar la homeostasis de la superficie ocular - Google Patents

Método para establecer, restablecer y preservar la homeostasis de la superficie ocular Download PDF

Info

Publication number
ES2909998T3
ES2909998T3 ES17817868T ES17817868T ES2909998T3 ES 2909998 T3 ES2909998 T3 ES 2909998T3 ES 17817868 T ES17817868 T ES 17817868T ES 17817868 T ES17817868 T ES 17817868T ES 2909998 T3 ES2909998 T3 ES 2909998T3
Authority
ES
Spain
Prior art keywords
eye
fluid
ocular surface
acid
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17817868T
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Georg Konrad Muller-Lierheim
Setten Gysbert-Botho Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICom Medical GmbH
I Com Medical GmbH
Original Assignee
ICom Medical GmbH
I Com Medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60766004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2909998(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ICom Medical GmbH, I Com Medical GmbH filed Critical ICom Medical GmbH
Application granted granted Critical
Publication of ES2909998T3 publication Critical patent/ES2909998T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES17817868T 2016-10-14 2017-10-02 Método para establecer, restablecer y preservar la homeostasis de la superficie ocular Active ES2909998T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408559P 2016-10-14 2016-10-14
US201762516911P 2017-06-08 2017-06-08
PCT/IB2017/001364 WO2018069763A1 (en) 2016-10-14 2017-10-02 Method for establishing, restoring, and preserving homeostasis of the ocular surface

Publications (1)

Publication Number Publication Date
ES2909998T3 true ES2909998T3 (es) 2022-05-11

Family

ID=60766004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17817868T Active ES2909998T3 (es) 2016-10-14 2017-10-02 Método para establecer, restablecer y preservar la homeostasis de la superficie ocular

Country Status (8)

Country Link
US (1) US20190240251A1 (https=)
EP (2) EP3871682A1 (https=)
JP (3) JP2019532105A (https=)
KR (1) KR20190068575A (https=)
ES (1) ES2909998T3 (https=)
HU (1) HUE058672T2 (https=)
PL (1) PL3525799T3 (https=)
WO (1) WO2018069763A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240251A1 (en) 2016-10-14 2019-08-08 i.com medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
CN112292135A (zh) 2018-04-18 2021-01-29 I.Com医疗有限责任公司 用于治疗和预防严重眼表疾病的高分子量透明质酸
CN112714644B (zh) * 2018-09-20 2024-03-29 香港科技大学 滴眼剂组合物
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
EP4106772A1 (en) * 2020-06-12 2022-12-28 i.com Medical GmbH High molecular weight hyaluronic acid for use in the treatment of corneal nerve damage or loss
PL4167965T3 (pl) * 2020-06-21 2025-03-24 i.com medical GmbH Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu
MX2024015185A (es) * 2022-06-08 2025-06-02 Schepens Eye Res Inst Metodos para tratar la enfermedad del ojo seco
EP4591860A1 (en) * 2024-01-23 2025-07-30 FB Vision S.p.A. Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JP3050898B2 (ja) * 1990-07-06 2000-06-12 千寿製薬株式会社 水性医薬製剤
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
SE9700827D0 (sv) * 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
US6528464B1 (en) * 2001-08-17 2003-03-04 Bausch & Lomb Incorporated Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels
JP3779200B2 (ja) * 2001-11-28 2006-05-24 電気化学工業株式会社 ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
MXPA05000186A (es) * 2002-07-03 2005-08-17 Pericor Science Inc Composiciones de acido hialuronico y metodos de uso.
DE10360425A1 (de) 2003-12-19 2005-07-28 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
CA2625532C (en) * 2005-10-12 2013-10-01 Seikagaku Corporation Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan
JP2008255061A (ja) * 2007-04-06 2008-10-23 Shiseido Co Ltd 可溶性架橋ヒアルロン酸含有眼用組成物
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
CN102026648A (zh) * 2008-05-15 2011-04-20 株式会社·R-技术上野 用于治疗干眼和/或角膜结膜损伤的药物组合物
JP5595206B2 (ja) * 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
US8283463B2 (en) * 2010-02-09 2012-10-09 Bausch & Lomb Incorporated Sterile hyaluronic acid solutions
CN103221422B (zh) * 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
PL2614838T3 (pl) * 2010-09-10 2016-10-31 Dikwafozol i kwas hialuronowy lub ich sole do zastosowania w leczeniu zespołu suchego oka
JP6692808B2 (ja) * 2014-12-02 2020-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ドライアイ用動物モデルおよびこうした動物の使用方法
JP6716293B2 (ja) * 2015-03-06 2020-07-01 参天製薬株式会社 眼科用組成物
US20170014339A1 (en) 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
US20190240251A1 (en) 2016-10-14 2019-08-08 i.com medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
CN112292135A (zh) * 2018-04-18 2021-01-29 I.Com医疗有限责任公司 用于治疗和预防严重眼表疾病的高分子量透明质酸
US12268706B2 (en) * 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain

Also Published As

Publication number Publication date
US20190240251A1 (en) 2019-08-08
JP2025029084A (ja) 2025-03-05
EP3525799B1 (en) 2022-01-26
EP3525799A1 (en) 2019-08-21
WO2018069763A1 (en) 2018-04-19
HUE058672T2 (hu) 2022-09-28
JP2022153583A (ja) 2022-10-12
KR20190068575A (ko) 2019-06-18
EP3871682A1 (en) 2021-09-01
JP2019532105A (ja) 2019-11-07
PL3525799T3 (pl) 2022-05-16

Similar Documents

Publication Publication Date Title
ES2909998T3 (es) Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
JP2020502197A (ja) ドライアイ疾患の治療のための眼科用組成物
CA3097470A1 (en) High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces
JP2008543877A (ja) Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
ES3008008T3 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
US12268706B2 (en) Hyaluronic acid for relief of idiopathic ocular pain
US20230241096A1 (en) High molecular weight hyaluronic acid for use in the treatment of corneal nerve damage or loss
EA046057B1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
EA050162B1 (ru) Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела
ES3056786T3 (en) Methods and compositions for reducing corneal endothelial cell loss